Rein Therapeutics Inc.
RNTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $14 | $0 | $0 | $0 |
| G&A Expenses | $14 | $0 | $0 | $0 |
| SG&A Expenses | $14 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $37 | $0 | $0 | $0 |
| Operating Expenses | $65 | $0 | $0 | $0 |
| Operating Income | -$65 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$64 | -$0 | -$0 | -$0 |
| Tax Expense | -$2 | $0 | $0 | $0 |
| Net Income | -$63 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS | -3.51 | -3.42 | -6.02 | -5.89 |
| % Growth | -2.6% | 43.2% | -2.2% | – |
| EPS Diluted | -3.51 | -3.42 | -6.02 | -5.89 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$28 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |